
Please try another search
NeuroScientific Biopharmaceuticals Limited engages in the research and development of novel peptide-based pharmaceutical products. The company is involved in the development of therapeutic treatments for neurodegenerative diseases through preclinical and clinical studies of patented technologies. Its lead drug candidates include EmtinB for treatment of neurodegenerative Alzheimer’s disease, multiple scierosis, glaucoma, optic nerve atrophy, and other diseases. The company was incorporated in 2002 and is based in Perth, Australia.
Name | Age | Since | Title |
---|---|---|---|
Paul Damien John Fry | - | 2025 | Director |
Dao-Yi Yu | - | 2020 | Member of Scientific Advisory Board |
Allan Kermode | - | 2021 | Member of Scientific Advisory Board |
Clarke Barlow | 43 | 2023 | Non-Executive Director |
Frank W. Bonner | 72 | 2021 | Member of Scientific Advisory Board |
Peter Hnik | 69 | 2021 | Member of Scientific Advisory Board |
Robert Leslie McKenzie | - | 2025 | Non-Executive Chairperson |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review